Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CSF1R | P07333 | 17/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4909008 | 1.00 | CYP3A4 (0.52) | CYP3A4CYP2C9CSF1RKCNH2 | |
| SCHEMBL4910625 | 0.89 | CSF1R (0.53) | CSF1R | |
| SCHEMBL4905307 | 0.89 | CSF1R (0.53) | CSF1R | |
| SCHEMBL4915359 | 0.89 | CSF1R (0.48) | CSF1R | |
| SCHEMBL4906603 | 0.87 | CSF1R (0.47) | CSF1R | |
| SCHEMBL4910516 | 0.86 | CSF1R (0.59) | CYP3A4CYP2C9CSF1R | |
| SCHEMBL4910568 | 0.86 | CSF1R (0.59) | CYP3A4CYP2C9CSF1R | |
| SCHEMBL4910573 | 0.86 | CSF1R (0.59) | CYP3A4CYP2C9CSF1R | |
| SCHEMBL5707279 | 0.86 | CYP3A4 (0.42) | CYP3A4CYP2C9CSF1RKCNH2 | |
| SCHEMBL27682418 | 0.85 | CSF1R (0.48) | CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | claimed |
| EP-1718615-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | claimed |
| WO-2005075429-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | claimed |
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| EP-1718615-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | AstraZeneca AB (SE) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005075429-A1 | NOVEL QUINOLINE-CARBAXAMIDES AS JACK3 KINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153799-A1 | Novel Quinoline-Carbaxamides as Jak3 Kinase Modulators | JAK3, JAK1, JAK2 | CYP3A4 1995/4885CYP2C9 2218/4885CSF1R 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.